AEON — Aeon Biopharma Balance Sheet
0.000.00%
- $4.53m
- $16.21m
- 2
- 100
- 15
- 32
Annual balance sheet for Aeon Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Cash | ||||
Cash and Short Term Investments | 5.13 | 9.75 | 5.16 | 0.013 |
Prepaid Expenses | ||||
Total Current Assets | 5.15 | 9.84 | 6.22 | 1.59 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 0.922 | 0.906 | 0.594 | 1.52 |
Other Long Term Assets | ||||
Total Assets | 6.44 | 10.8 | 6.84 | 3.14 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 20.8 | 82.6 | 13 | 14.1 |
Long Term Debt | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Minority Interest | ||||
Total Other Liabilities | ||||
Total Liabilities | 103 | 160 | 160 | 31.7 |
Redeemable Preferred Stock | ||||
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Treasury Stock | ||||
Other Equity | ||||
Total Equity | -97 | -150 | -153 | -28.6 |
Total Liabilities & Shareholders' Equity | 6.44 | 10.8 | 6.84 | 3.14 |
Total Common Shares Outstanding |